SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of October 6, 2015
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82 -
EXHIBIT
NUMBER |
|
DESCRIPTION |
| |
|
|
| 99.1 |
|
News
Release Dated October 6, 2015 - Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Prostate Cancer Study |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Oncolytics Biotech Inc.
(Registrant) |
| |
|
|
| |
|
|
| Date:
October 6, 2015 |
By: |
/s/ Kirk Look |
| |
|
Kirk Look |
| |
|
Chief Financial Officer |
Exhibit 99.1
Oncolytics Biotech® Inc. Announces
Completion of Enrollment in Randomized Phase II Prostate Cancer Study
CALGARY, Oct. 6, 2015 /CNW/ - Oncolytics Biotech® Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Phase II study
of REOLYSIN® in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial
is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston,
Ontario.
"Prostate cancer remains a leading cause
of cancer-related death in men," said Dr. Brad Thompson, President and CEO of Oncolytics. "As a result, it is important
that we continue to conduct studies with late-stage patients to help improve outcomes for this group."
The study is an open-label, randomized, non-blinded,
Phase II clinical study of REOLYSIN® given in combination with docetaxel versus docetaxel alone. Approximately 40
response evaluable patients were enrolled in each arm.
The primary objective of the trial is to evaluate
the efficacy of REOLYSIN® in combination with docetaxel based on the lack of disease progression as measured at
12 weeks. Secondary objectives are to determine circulating tumour cell status at six and 12 weeks and the conversion rate
of these cells, prostate-specific antigen (PSA) change rate, objective response rate (in patients with measurable disease at baseline),
effect on overall survival, the tolerability and toxicity of the treatment combination, and to explore potential molecular factors
predictive of response.
Although accrual is complete, patient follow-up
will continue until planned analyses have been conducted.
About Prostate Cancer
Prostate cancer is among the most common cancers diagnosed in men. The Canadian Cancer Society estimates that 24,000 Canadian men
will be diagnosed with prostate cancer and that 4,100 Canadian men are expected to die from the disease in 2015. The American
Cancer Society estimates that 220,800 new cases of prostate cancer will be diagnosed in the United States and that 27,450 Americans
are expected to die from the disease in 2015.
About the NCIC Clinical Trials Group at
Queen's University
The NCIC Clinical Trials Group (NCIC CTG) is a cancer clinical trials cooperative group that conducts Phase I-III trials testing
anti-cancer and supportive therapies across Canada and internationally. It is a national research program of the Canadian
Cancer Society. The NCIC CTG's Central Operations and Statistics Office is located at Queen's University in Kingston, Ontario,
Canada.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking
statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended,
and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical
facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will
or may occur in the future, including such things as, the Company's expectations related to the Phase II prostate cancer trial
sponsored by the NCIC CTG, the Company's belief as to the potential of REOLYSIN® as a cancer therapeutic,
and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements
and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency
of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside
a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
REOLYSIN®, uncertainties related to the research and development of pharmaceuticals and uncertainties related to
the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking statements and forward-looking
information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information.
The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.
%CIK: 0001129928
For further information: NATIONAL Equicom, Nick Hurst, 800
6th Ave. SW, Suite 1600, Calgary, Alberta T2P 3G3, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@national.ca; NATIONAL Equicom,
Michael Moore, San Diego, CA, Tel: 858.886.7813, mmoore@national.ca; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd
Floor, New York, NY 10018, Tel: 212.825.3210. Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 06-OCT-15